Beauty Farm Medical and Health Industry Inc. (FRA:XC5)
Germany · Delayed Price · Currency is EUR 2.780
0.00 (0.00%)
Last updated: Jan 26, 2026, 8:00 AM CET
FRA:XC5 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 2,894 | 2,572 | 2,145 | 1,635 | 1,781 | 1,503 | |
Revenue Growth (YoY) | 28.84% | 19.91% | 31.16% | -8.16% | 18.46% | 7.02% |
Cost of Revenue | 1,518 | 1,382 | 1,168 | 917.57 | 946.95 | 803.27 |
Gross Profit | 1,376 | 1,190 | 977.1 | 717.84 | 833.79 | 700.02 |
Selling, General & Admin | 966.54 | 849.84 | 696.52 | 575.38 | 571.91 | 494.58 |
Research & Development | 40.77 | 36.03 | 34.07 | 31.19 | 18.03 | 12.67 |
Other Operating Expenses | -5.25 | -9.03 | -22.42 | -24.44 | -14.96 | -9.14 |
Operating Expenses | 1,006 | 880.74 | 708.12 | 582.11 | 576.29 | 496.09 |
Operating Income | 369.12 | 309.25 | 268.99 | 135.73 | 257.49 | 203.93 |
Interest Expense | -29.05 | -27.56 | -24.81 | -24.71 | -24.22 | -25.93 |
Interest & Investment Income | 24.28 | 23.62 | 21.84 | 3.09 | 1.28 | 1.13 |
Earnings From Equity Investments | - | - | -0.05 | - | - | - |
Currency Exchange Gain (Loss) | 1.25 | -2.55 | 0.32 | 4.03 | -0.23 | -0.46 |
Other Non Operating Income (Expenses) | 0.89 | 0.89 | -0.85 | -0.18 | - | - |
EBT Excluding Unusual Items | 366.48 | 303.65 | 265.43 | 117.97 | 234.34 | 178.68 |
Gain (Loss) on Sale of Investments | 17.71 | 20.93 | 23.85 | 20.7 | 23.41 | 13.43 |
Gain (Loss) on Sale of Assets | -6.47 | -7.08 | -1.01 | -0.91 | -2.64 | -3.57 |
Other Unusual Items | 0.38 | 0.38 | - | -7.28 | - | - |
Pretax Income | 378.1 | 317.88 | 288.27 | 130.48 | 255.1 | 188.53 |
Income Tax Expense | 80.92 | 65.41 | 58.13 | 19.94 | 46.76 | 36.35 |
Earnings From Continuing Operations | 297.18 | 252.48 | 230.14 | 110.53 | 208.34 | 152.19 |
Minority Interest in Earnings | -28.46 | -24.02 | -14.48 | -7.42 | -14.87 | -1.23 |
Net Income | 268.72 | 228.46 | 215.66 | 103.11 | 193.48 | 150.96 |
Net Income to Common | 268.72 | 228.46 | 215.66 | 103.11 | 193.48 | 150.96 |
Net Income Growth | 22.56% | 5.94% | 109.15% | -46.71% | 28.16% | 7.58% |
Shares Outstanding (Basic) | 230 | 230 | 229 | 200 | 200 | 200 |
Shares Outstanding (Diluted) | 230 | 230 | 230 | 200 | 200 | 200 |
Shares Change (YoY) | -0.15% | -0.14% | 14.99% | 0.24% | - | - |
EPS (Basic) | 1.17 | 0.99 | 0.94 | 0.52 | 0.97 | 0.76 |
EPS (Diluted) | 1.17 | 0.99 | 0.94 | 0.52 | 0.97 | 0.76 |
EPS Growth | 23.18% | 5.32% | 82.26% | -46.79% | 28.16% | 7.58% |
Free Cash Flow | 922.34 | 682.44 | 466.27 | 241.21 | 536.76 | 613.03 |
Free Cash Flow Per Share | 4.01 | 2.97 | 2.03 | 1.21 | 2.69 | 3.07 |
Dividend Per Share | 0.480 | 0.480 | 0.427 | 0.345 | - | - |
Dividend Growth | 12.51% | 12.51% | 23.67% | - | - | - |
Gross Margin | 47.54% | 46.26% | 45.55% | 43.89% | 46.82% | 46.57% |
Operating Margin | 12.76% | 12.02% | 12.54% | 8.30% | 14.46% | 13.57% |
Profit Margin | 9.29% | 8.88% | 10.05% | 6.30% | 10.87% | 10.04% |
Free Cash Flow Margin | 31.88% | 26.53% | 21.74% | 14.75% | 30.14% | 40.78% |
EBITDA | 525.4 | 450.36 | 386.33 | 242.01 | 356.27 | 302.43 |
EBITDA Margin | 18.16% | 17.51% | 18.01% | 14.80% | 20.01% | 20.12% |
D&A For EBITDA | 156.28 | 141.11 | 117.35 | 106.28 | 98.78 | 98.5 |
EBIT | 369.12 | 309.25 | 268.99 | 135.73 | 257.49 | 203.93 |
EBIT Margin | 12.76% | 12.02% | 12.54% | 8.30% | 14.46% | 13.57% |
Effective Tax Rate | 21.40% | 20.57% | 20.16% | 15.29% | 18.33% | 19.28% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.